Related Experiment Video
Updated: Jun 23, 2026

Experimental Metastasis Assay
Published on: August 24, 2010
Altered gene and protein expression by Nm23-H1 in metastasis suppression
Jong Heun Lee1, Jean-Claude Marshall, Patricia S Steeg
1Women's Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 1122, Bethesda, MD 20892, USA.
Abstract:
Metastasis suppressor genes (MSG) are characterized by their ability to inhibit the formation of metastasis, while not affecting the growth of the primary tumor in vivo. Nm23-H1, the first MSG to be characterized, has been shown to alter both gene and protein expression in cancer cells. Recently, microarray expression profiling revealed that Nm23-H1 downregulated EDG2, which encodes for a lysophosphatidic acid (LPA) receptor. Reintroduction of EDG2 into cells that express Nm23-H1 overcame the metastasis suppressive ability of Nm23-H1 in both in vivo pulmonary colonization and spontaneous metastasis assays. In addition, isotope capture affinity tag (ICAT) proteomic analysis was performed to identify differentially expressed proteins not accounted for by microarray analysis. ICAT identified several differentially regulated proteins, including GEMIN5, a protein involved in differential mRNA splicing. The contribution of alternative mRNA splicing to cancer and cancer metastasis is poorly defined. It is possible that Nm23-H1, through the regulation of RNA processing proteins, may play a role in proteome stability.
Insights
Metastasis suppressor genes like Nm23-H1 inhibit cancer spread by downregulating EDG2 and potentially influencing mRNA splicing. Restoring EDG2 counteracts Nm23-H1’s metastasis-suppressive effects, highlighting its role in cancer progression.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Metastasis suppressor genes (MSG) inhibit cancer spread without affecting primary tumor growth.
- Nm23-H1 is the first identified MSG, known to modulate gene and protein expression in cancer cells.
Purpose of the Study:
- To investigate the molecular mechanisms by which Nm23-H1 suppresses metastasis.
- To identify downstream targets of Nm23-H1 and their role in metastasis.
Main Methods:
- Microarray expression profiling to identify downregulated genes.
- In vivo metastasis assays (pulmonary colonization and spontaneous metastasis).
- Isotope Capture Affinity Tag (ICAT) proteomic analysis to identify differentially expressed proteins.
Main Results:
- Nm23-H1 was found to downregulate EDG2, which encodes a lysophosphatidic acid (LPA) receptor.
- Reintroducing EDG2 into Nm23-H1-expressing cells reversed the metastasis suppressive phenotype.
- ICAT analysis identified GEMIN5, a protein involved in mRNA splicing, as differentially regulated.
Conclusions:
- EDG2 plays a critical role in mediating the metastasis suppressive function of Nm23-H1.
- Nm23-H1 may influence cancer metastasis through the regulation of RNA processing proteins and alternative mRNA splicing.
- Further research into Nm23-H1's role in RNA processing could reveal new therapeutic strategies for cancer metastasis.
Related Concept Videos
Abnormal Proliferation
MicroRNAs
MicroRNAs
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
